China NT Pharma Group Co., Ltd. (HK:1011) has released an update.
China NT Pharma Group Co., Ltd. has terminated a significant acquisition regarding the commercialization rights due to technical issues and a change in the company’s focus towards its core bone health business. Additionally, the company announced a reallocation of the unused HK$2.9 million from the net proceeds of a recent share placing, which will now be directed towards working capital and general corporate purposes to improve financial flexibility.
For further insights into HK:1011 stock, check out TipRanks’ Stock Analysis page.
